首页> 美国卫生研究院文献>Cancer Science >Nuclear p53 Immunoreaction Associated with Poor Prognosis of Breast Cancer
【2h】

Nuclear p53 Immunoreaction Associated with Poor Prognosis of Breast Cancer

机译:核p53免疫反应与乳腺癌预后不良有关

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

p53 protein has been frequently detected at high levels in the nuclei of human breast cancer cells. We analyzed inununohistochemically the association between nuclear localization of p53 protein and clinical and histological parameters of breast cancer patients. Surgically resected tissues of 73 primary breast cancers were processed by acetone fixation and paraffin embedding and examined using an anti‐p53 monoclonal antibody, Pabl801. p53 immunoreactivity was detected in the nuclei of cancer cells in 17 cases (23%). The nuclear p53 immunoreaction was closely associated with overexpression of c‐erbB‐2 protein (P<0.05), high histologic grade (P<0.01), advanced clinical stage (P<0.05), and negative estrogen receptor status (P< 0.01). When 31 cases which had been followed up for more than 50 months were examined, a positive nuclear p53 immunoreaction was found to he significantly associated with shorter overall survival of patients (P<0.01). These results suggest that inununohistochemical examination of nuclear p53 protein is clinically useful as an indicator of breast cancer aggressiveness.
机译:在人类乳腺癌细胞核中经常高水平检测到p53蛋白。我们分析了p53蛋白的核定位与乳腺癌患者的临床和组织学参数之间的关系。 73例原发性乳腺癌的手术切除组织通过丙酮固定和石蜡包埋处理,并使用抗p53单克隆抗体Pabl801进行检查。在17例癌细胞的细胞核中检测到p53免疫反应性(23%)。核p53免疫反应与c-erbB-2蛋白的过表达(P <0.05),组织学分级高(P <0.01),临床晚期(P <0.05)和雌激素受体阴性(P <0.01)有密切关系。 。当检查了31例随访超过50个月的病例时,发现其核p53阳性免疫反应与患者总体生存期缩短显着相关(P <0.01)。这些结果表明,核组织p53蛋白的免疫组织化学检查在临床上可作为乳腺癌侵袭性的指标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号